A retinitis pigmentosa genetic test searches for inherited variants that damage retinal photoreceptors or supporting cells. Retinitis pigmentosa (RP) is not one disease caused by one gene. It is a clinical pattern of progressive retinal degeneration that may be autosomal dominant, autosomal recessive, X-linked, mitochondrial, or rarely digenic. The same symptoms can also be part of a syndrome affecting hearing, kidneys, metabolism, development, or other organs.
Because many genes produce overlapping retinal findings, testing usually begins with a broad inherited retinal disease panel rather than a single-gene test. A molecular diagnosis can confirm the cause, clarify relatives’ risks, identify syndromic health needs, and determine possible eligibility for gene-specific therapy or research. It cannot predict the exact rate of vision loss. A negative result does not erase a well-supported clinical diagnosis, and a variant of uncertain significance should not be treated as proof. The best interpretation combines the report with retinal imaging, visual fields, electroretinography, age of onset, family history, and examination by an inherited retinal disease specialist.
- RP often begins with night blindness and progressive peripheral visual-field loss.
- More than 50 genes cause nonsyndromic RP, and many additional genes cause syndromic retinal degeneration.
- Inheritance cannot always be determined reliably from the family tree alone.
- A multigene panel should include copy-number analysis and relevant difficult-to-detect variants when possible.
- A positive result may change medical screening beyond the eyes if the gene causes a syndrome.
- Genetic results should be retained because reanalysis, trials, and treatment options change over time.
Table of Contents
- Why RP requires broad genetic testing
- The eye evaluation before genetic testing
- Genes and inheritance patterns
- Reading positive, negative, and uncertain results
- When the result points beyond the eye
- Treatment, trials, and what genotype can predict
- Family testing and reproductive planning
- What to do after an inconclusive test
Why RP requires broad genetic testing
The retina contains rod photoreceptors, which support dim-light and peripheral vision, and cone photoreceptors, which support central detail and color. In many forms of RP, rods become dysfunctional first. People notice difficulty seeing in the dark, slow adaptation between bright and dim settings, or trouble navigating in side vision. As degeneration progresses, the visual field narrows and cones may also be affected.
The label RP describes this pattern, not its molecular cause. Pathogenic variants can affect phototransduction, ciliary transport, vitamin A metabolism, RNA splicing, protein folding, the visual cycle, outer-segment structure, or retinal pigment epithelium function. This diversity explains why two people with similar retinal images can have different genes and inheritance risks.
Commonly implicated genes include RHO, PRPF31, PRPH2, RP1, USH2A, EYS, PDE6A, PDE6B, CNGB1, ABCA4, RPE65, CRB1, NR2E3, CERKL, RPGR, RP2, and many others. Some genes are associated with more than one retinal diagnosis. For example, a gene may cause classic rod-cone degeneration in one person and cone-rod dystrophy, Leber congenital amaurosis, or macular disease in another.
A broad genetic panel is therefore usually more efficient than sequential single-gene testing. The panel should be designed for inherited retinal disease, not a generic exome slice with uncertain coverage. Important assay features include sequencing, deletion/duplication analysis, coverage of difficult regions such as the repetitive RPGR ORF15 exon, and detection of known deep intronic or structural variants when validated.
Some laboratories offer exome or genome sequencing as a first or second test. These methods may help when the phenotype is atypical or includes non-eye features, but coverage and interpretation of retinal genes still need review. A large test is not automatically a complete test.
Genetic testing is appropriate even without a family history. Recessive disease often appears in a single generation. X-linked disease may pass silently through females. A dominant variant may be new in the affected person, and mild disease in relatives may have gone unrecognized. Small families, early deaths, adoption, and limited access to eye care can also hide inheritance.
The eye evaluation before genetic testing
A careful phenotype makes genetic testing more accurate. The ophthalmologist does not need to know the exact gene before ordering a panel, but the clinical pattern helps the laboratory prioritize findings and avoid overinterpreting irrelevant variants.
The assessment may include:
- Best-corrected visual acuity and refraction
- Dilated retinal examination
- Optical coherence tomography to show photoreceptor and retinal-layer structure
- Fundus autofluorescence to map stressed or lost retinal pigment epithelium
- Full-field or multifocal electroretinography to measure retinal function
- Kinetic or static visual-field testing
- Color testing and dark-adaptation assessment when useful
- Wide-field photography and other retinal imaging
Classic RP findings can include narrowed retinal vessels, waxy optic-disc pallor, and pigment deposits described as bone spicules. Early disease may not show all of these signs. Some genetic forms have little pigment, sectoral disease, preserved central islands, early macular change, or a distinctive autofluorescence pattern.
Age at first symptoms matters. Severe visual dysfunction in infancy raises different possibilities from night blindness beginning in adolescence or adult-onset field loss. The history should ask about hearing, balance, kidney disease, obesity, diabetes, developmental differences, polydactyly, neurologic symptoms, medication exposure, trauma, and inflammatory or infectious disease. These details can reveal a syndrome or a non-genetic mimic.
Family history should include relatives with poor night vision, driving difficulty, unexplained blindness, hearing loss, or a diagnosis that may have been recorded as “macular degeneration.” Male relatives connected through maternal lines can suggest X-linked disease, while affected people in successive generations can suggest dominant inheritance. However, pedigree appearance alone is not definitive.
The clinician should also distinguish RP from acquired retinal toxicity, autoimmune retinopathy, post-infectious damage, vitamin deficiency, and other degenerations. A genetic finding must fit the phenotype. Discovering one pathogenic variant in a recessive gene does not prove that it explains an acquired retinal disorder.
Pretest counseling should set realistic expectations. A positive result may provide a precise name without changing current treatment. A negative result may remain unresolved. Incidental or syndromic information may emerge, and testing can reveal unexpected biological relationships. These possibilities are easier to manage when discussed before the sample is collected.
Genes and inheritance patterns
RP can follow several inheritance patterns, each with different family risks.
Autosomal dominant RP
One pathogenic variant can be sufficient. An affected person generally has a 50% chance of passing it to each child. Dominant genes include RHO, PRPF31, PRPH2, RP1, IMPDH1, SNRNP200, and others. Severity and age of onset may vary widely within a family.
Some dominant variants have reduced penetrance, meaning a person can carry the variant with mild or no recognized retinal disease. PRPF31 is a well-known example. An apparently unaffected parent can therefore transmit a variant to a more clearly affected child. Reduced penetrance complicates risk prediction and requires examination of relatives rather than assumptions based on symptoms.
Autosomal recessive RP
Most recessive RP requires two pathogenic variants in the same gene, one on each chromosome copy. Parents are usually unaffected carriers. If both parents carry a variant in the same gene, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child who inherited neither variant.
Recessive genes include USH2A, EYS, PDE6A, PDE6B, CNGB1, CRB1, RPE65, CERKL, and many more. Two reportable variants must usually be shown or strongly inferred to be in trans. Two variants in cis on the same copy do not establish recessive disease.
X-linked RP
X-linked RP is often caused by RPGR or RP2. Males with a pathogenic variant on their only X chromosome are usually affected and may have relatively early, severe disease. Females with one variant can range from no symptoms to substantial retinal degeneration because X-chromosome inactivation differs among retinal cells.
An affected male passes the variant to all daughters and no sons. A female carrier has a 50% chance of passing it in each pregnancy. Sons who inherit it are typically affected; daughters who inherit it may be carriers with variable manifestations. A dedicated X-linked inheritance guide can help families visualize these patterns.
Mitochondrial and digenic inheritance
Rare RP-like disorders follow mitochondrial inheritance, in which a mother can transmit a mitochondrial variant to all children while an affected father does not transmit it. Digenic disease requires a specific combination of variants in two different genes, such as certain PRPH2 and ROM1 combinations. These situations require specialist interpretation because ordinary dominant or recessive rules do not apply.
Why the pedigree can mislead
A recessive condition can appear dominant when affected people partner with carriers. X-linked disease can appear to pass through several generations of females. A dominant condition with reduced penetrance can skip apparent generations. Molecular testing therefore provides more reliable recurrence counseling than pedigree pattern alone.
Reading positive, negative, and uncertain results
A useful report identifies the gene, transcript, exact DNA and protein change, classification, zygosity, predicted inheritance, and test limitations. Interpretation depends on both the variant and the gene’s disease mechanism.
Pathogenic or likely pathogenic result
A single pathogenic or likely pathogenic variant in a dominant gene can confirm the molecular diagnosis when the phenotype fits. Two such variants in trans in a recessive gene can also confirm it. One pathogenic variant in an X-linked gene may confirm disease in a male and carrier or manifesting-carrier status in a female.
“Likely pathogenic” is a formal classification supported by strong evidence. It is generally used clinically like pathogenic, although laboratories continue to gather data. The result may explain inheritance and gene-specific health risks even if it cannot predict exact progression.
One variant in a recessive gene
One pathogenic variant usually indicates carrier status, not the cause of RP. The second variant may be missed because it is deep intronic, structural, in a poorly covered region, or not recognized by current interpretation. Alternatively, the retinal disease may be caused by another gene. A clinician should not force a diagnosis from one allele simply because the gene is plausible.
Negative result
A negative result means no reportable causal finding was identified by that assay. It does not rule out inherited retinal disease. Diagnostic yield varies with phenotype, ancestry, test design, and prior analysis. Possible reasons include a variant outside captured regions, a structural or mitochondrial change, mosaicism, a newly discovered gene, or a phenotype that was classified too broadly.
A negative result is more informative for a relative when the family’s causal variant is already known. If the relative tests negative for that exact variant, their risk from that familial condition is usually greatly reduced or removed, depending on the inheritance pattern.
Variant of uncertain significance
A VUS is not a diagnosis. It may later be reclassified as pathogenic or benign. The laboratory may seek family segregation, population frequency, functional evidence, RNA effects, or reports of other affected people. Clinical care should not be based on the VUS alone, and relatives should not be labeled affected or unaffected from it without a structured plan.
In recessive disease, one pathogenic variant plus one VUS may be suspicious but remains incomplete. In dominant disease, a VUS in a relevant gene can be tempting to overinterpret because only one variant is expected. Phenotype fit and evidence standards still matter. A variant classification guide explains these categories in more detail.
Unexpected or secondary finding
A broad exome or genome can identify findings unrelated to the eye question. Consent policies differ regarding secondary findings. An inherited retinal panel is narrower and generally reduces this possibility, although a retinal gene itself may have systemic implications.
When the result points beyond the eye
A major benefit of genetic testing is recognizing that retinal degeneration may be the first visible part of a multisystem condition. Early identification can prompt surveillance before another complication becomes severe.
Usher syndrome combines RP with hearing loss and sometimes vestibular dysfunction. Genes include USH2A, MYO7A, CDH23, PCDH15, USH1C, ADGRV1, CLRN1, and others. Hearing loss may be congenital or progressive. A person referred for “isolated RP” may not realize that longstanding hearing difficulty is genetically connected.
Bardet-Biedl syndrome can include retinal degeneration, obesity, kidney disease, polydactyly, hypogonadism, and learning differences. Features emerge at different ages, so a child may initially have only vision findings.
Alström syndrome, caused by ALMS1, can include cone-rod degeneration, hearing loss, cardiomyopathy, obesity, diabetes, and organ fibrosis. Senior-Løken syndrome and other nephronophthisis-related ciliopathies combine retinal degeneration with kidney disease. Certain mitochondrial disorders add neurologic, cardiac, or metabolic findings.
Other genes can be associated with ataxia, neuropathy, developmental differences, skeletal abnormalities, or treatable metabolic disease. The report should not merely name the syndrome; it should trigger appropriate referrals and confirmatory evaluation. Gene-related risk does not mean every listed feature is present.
The reverse is also important. A person with an USH2A variant does not have Usher syndrome unless the full genotype and clinical findings support it. Some genes cause both syndromic and nonsyndromic disease depending on the variants. Two variants may be needed, and variant severity can influence whether hearing or systemic features occur.
After a syndromic result, care may involve audiology, nephrology, cardiology, endocrinology, neurology, developmental services, or other specialties. The ophthalmologist and genetics team should explain which risks are established, which are possible, and what baseline testing is reasonable.
This information can be emotionally difficult because a test ordered for vision may introduce a new health concern. It can also be protective. Identifying kidney, hearing, or cardiac risk before symptoms allows planned surveillance rather than crisis diagnosis.
Treatment, trials, and what genotype can predict
A molecular diagnosis may be necessary for gene-specific therapy, but testing does not guarantee that a treatment exists or that a person qualifies.
An approved retinal gene therapy is available in some countries for people with confirmed biallelic RPE65-associated retinal dystrophy who meet retinal-viability and other clinical criteria. The same gene can cause different clinical labels, so eligibility depends on genotype and examination rather than whether the chart says RP or Leber congenital amaurosis.
Many studies are evaluating gene augmentation, gene editing, antisense oligonucleotides, optogenetics, neuroprotection, cell-based approaches, and mutation-independent therapies. Trial criteria may specify the gene, exact variant class, age, visual acuity, visual field, retinal thickness, prior treatment, and evidence of remaining photoreceptors. A patient should not change care or pay for an unapproved intervention based on online claims.
Genotype can suggest broad natural-history patterns. X-linked RP due to many RPGR variants is often severe in males. Some RHO or PRPH2 variants produce regional or variable disease. Certain genes are associated with early macular involvement, cystoid macular edema, or preserved central vision. Yet the same variant can produce different progression in different people.
Serial clinical measurements are more useful than genotype alone for individual prognosis. Optical coherence tomography, autofluorescence, visual fields, acuity, and electroretinography can show remaining structure and change over time. The gene explains why degeneration occurs; longitudinal testing shows what it is doing in that person.
Current management may include low-vision rehabilitation, orientation and mobility training, workplace or school accommodations, glare control, treatment of cataract or cystoid macular edema when appropriate, and psychosocial support. Driving and occupational decisions should be based on measured visual function and local rules, not the gene name.
High-dose supplements should not be started from internet advice. Older vitamin A recommendations do not apply safely to every genotype or person and can pose liver, pregnancy, and other risks. Some genetic conditions may be harmed by particular supplements. Nutritional or drug decisions should be reviewed with an inherited retinal specialist.
A result may also help avoid ineffective therapy. If retinal degeneration is part of a syndrome or a different inherited retinal phenotype, treatment and surveillance priorities may change. The value of diagnosis is therefore broader than trial enrollment.
Family testing and reproductive planning
Once the causal variants are known, targeted family testing is faster and clearer than ordering broad panels for everyone. The family should share the complete report, not a handwritten gene name, because exact variants and classifications matter.
Testing may clarify whether relatives need eye examinations, whether apparently unaffected adults carry a dominant or X-linked variant, and whether partners should be screened for a recessive gene. Predictive testing of minors is most appropriate when childhood surveillance, treatment, educational planning, or safety may benefit. The decision should respect the child’s interests and the condition’s expected age of onset.
For recessive RP, the partner of an affected person is usually offered testing of the specific gene. If the partner is not a carrier by a comprehensive test, the chance of an affected child is reduced but not always zero. If both partners carry pathogenic variants in the same gene, each pregnancy has a 25% affected risk.
For dominant RP, an affected person generally has a 50% chance of passing the variant to each child, but penetrance and severity may vary. For X-linked RP, risk depends on which parent carries the variant and the child’s sex chromosomes. Counseling should include the possibility of substantial retinal disease in female carriers.
Reproductive options may include natural conception without testing, prenatal diagnosis, in vitro fertilization with preimplantation genetic testing for a monogenic condition, donor gametes, adoption, or choosing not to have children. None is universally correct. A confirmed pathogenic variant is usually required for embryo or fetal testing; a VUS is a poor target because its meaning is unresolved.
Prenatal testing can determine whether a fetus inherited the variant but usually cannot predict exact visual severity or age of onset. The family should discuss this limitation before testing. Information about prenatal genetic testing can prepare people for a genetics consultation.
A diagnosis can also reveal unexpected nonpaternity, donor conception, or other biological relationships. Laboratories and clinics should have a plan for communicating such findings. Pretest counseling helps families decide how much information they wish to receive.
What to do after an inconclusive test
An inconclusive result is common enough that the next step should be planned, not treated as failure.
First, verify what was actually tested. Did the panel include the suspected genes? Was RPGR ORF15 well covered? Were copy-number variants assessed? Were mitochondrial DNA and known deep intronic variants included? Did the laboratory analyze syndromic genes? A panel ordered years ago may be much narrower than a current test.
Second, review whether the phenotype needs refinement. Updated retinal imaging, electroretinography, hearing testing, kidney evaluation, or examination of affected relatives can point to a different gene set. A more precise diagnosis such as cone-rod dystrophy, choroideremia, enhanced S-cone syndrome, or inherited macular dystrophy may improve analysis.
Third, consider testing another affected relative. A relative with a clearer or more severe phenotype may be more informative. Family testing can also determine phase or show whether a candidate variant tracks with disease.
Fourth, consider reanalysis or a different technology. Exome reanalysis may identify a gene discovered after the original report. Genome sequencing can improve detection of noncoding and structural variants, although interpretation remains challenging. RNA testing from an appropriate tissue or laboratory model can confirm a suspected splice effect. Long-read sequencing can resolve complex regions or phase distant variants.
Fifth, retain all records. Keep color copies of retinal images when available, the original molecular report, raw-data access information, and the clinic’s phenotype summary. Do not assume the laboratory will contact the family indefinitely. Ask when reanalysis is recommended and whether an amended report will be issued after reclassification.
A clinical diagnosis remains meaningful while molecular work continues. Low-vision services, safety planning, school accommodations, and treatment of complications should not wait for a gene result. At the same time, an unexplained retinal degeneration should be periodically revisited because diagnostic methods and gene-disease knowledge are changing rapidly.
Direct-to-consumer genotyping cannot rule out RP and should not be used to enroll in a trial. Consumer arrays test a small set of variants and can produce false positives in rare disease genes. Any finding with medical implications must be confirmed in a clinical laboratory.
Seek urgent ophthalmic care for sudden new vision loss, flashes with a curtain-like shadow, severe eye pain, or acute neurologic symptoms. RP usually progresses gradually; a sudden change may represent a retinal tear, detachment, vascular event, inflammation, or another treatable emergency rather than ordinary progression.
References
- Nonsyndromic Retinitis Pigmentosa Overview. 2023. GeneReviews.
- Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations. 2022. American Academy of Ophthalmology clinical statement.
- The current state of genetic testing platforms for inherited retinal diseases. 2022. Review.
- Spectrum of Genetic Variants in the Most Common Genes Causing Inherited Retinal Disease in a Large Molecularly Characterized United Kingdom Cohort. 2024. Original research.
- Patient experiences and perceived value of genetic testing in inherited retinal diseases. 2024. Original research.
Disclaimer
This article provides general education and does not diagnose retinitis pigmentosa, predict an individual’s vision loss, or determine treatment or trial eligibility. Genetic results should be interpreted with retinal examination and imaging by an inherited retinal disease specialist and a qualified genetics professional. Sudden vision loss, new flashes with a curtain or shadow, severe eye pain, or acute neurologic symptoms requires urgent medical assessment.
